Arcus Biosciences to Present Final Results from the Phase 1 Study of AB928 in Healthy Volunteers at ESMO 2018 Congress

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that it will present final results from the Phase 1 study of AB928, its dual adenosine receptor antagonist, in healthy volunteers during a poster display session at the European Society of Medical Oncology (ESMO) 2018 Congress, being held October 19-23, 2018, in Munich, Germany. The safety data to be presented will demonstrate that in this study, there was no evidence of the physiological effects of blocking adenosine that have been observed clinically with earlier adenosine receptor antagonists. Physiological effects associated with the earlier adenosine receptor antagonists that were initially designed for CNS indications may potentially limit their optimal dosing in the oncology setting. The pharmacokinetic and pharmacodynamic correlations generated from this study, which will be described in the poster presentation, were used to guide dose selection in the Company’s four Phase 1/1b trials in patients. Details of the poster presentation are as follows: Abstract Number: 1880P Poster Title: Final results of the Phase 1 study in healthy volunteers of AB928, a dual antagonist of the A 2a R and A 2b R adenosine receptors being studied as an activator of anti-tumor immune response. Poster display session: Biomarkers, Gynecological cancers, Hematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research (ID 259) Session Date and Time: Saturday, Oct. 20, 2018, 12:30 - 1:30 pm CEST Location: Hall A3 The poster will be available at www.arcusbio.com/publications . About AB928 AB928 is an orally bioavailable, highly potent antagonist of the adenosine 2a and 2b receptors. The activation of these receptors by adenosine interferes with the activity of key populations of immune cells and inhibits an optimal anti-tumor immune response. By blocking these receptors, AB928 has the potential to reverse adenosine-induced immune suppression within the tumor microenvironment. AB928 was designed specifically for the oncology setting, with a profile that includes potent activity in the presence of high concentrations of adenosine and a minimal shift in potency due to non-specific protein binding, both essential properties for efficacy in the tumor microenvironment. AB928 has other attractive features, including high penetration of tumor tissue and low penetration through the healthy blood-brain barrier. In a Phase 1 trial in healthy volunteers, AB928 has been shown to be safe and well tolerated and to have pharmacokinetic and pharmacodynamic profiles consistent with a once-daily dosing regimen. The Company has initiated four phase 1/1b trials evaluating AB928 in combination with other agents in selected tumor types. About Arcus Biosciences Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates. Arcus’s other programs include AB154, an anti-TIGIT antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy and in combination with AB122, and AB680, a small molecule inhibitor of CD73, which is in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. For more information about Arcus Biosciences, please visit www.arcusbio.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20181008005818/en/ Arcus Biosciences Jennifer Jarrett, 510-694-6261 [email protected] or Nicole Arndt, 510-284-4728 [email protected] Source: Arcus Biosciences Investor Contact [email protected] Investor Email Alerts To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time. * Required Email Address * Mailing Lists * Press Releases Events SEC Filings EOD Stock Quote Email Alert Sign Up Confirmation Explore More Read our latest press releases and announcements Browse Join forces with us on our mission to defeat cancer Connect Arcus clinical trials are currently enrolling Sign up Arcus Biosciences is a registered trademark of Arcus Biosciences, Inc. © Arcus Biosciences, Inc. All rights reserved. 3928 Point Eden Way, Hayward, CA 94545 About Us Our Science Editorials Careers Investors & Media Contact Terms of Use Sitemap Privacy Policy Washington Health Data Privacy Policy Cookie Policy DO NOT SELL/SHARE MY PERSONAL INFORMATION Powered By Q4 Inc. 5.187.1.9 (opens in new window)

The release as fetched from its publisher. arcusbio.com ↗